The PrEP Access and Coverage Act of 2026 would expand access to HIV prevention medications, including pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP), across a wide range of health coverage programs. It requires most private health plans, grandfathered plans, employer plans governed by ERISA, the federal employee health benefits program, Medicaid, CHIP, Medicare, TRICARE, the Veterans Health Administration, and Indian Health Service programs to cover FDA-approved HIV prevention drugs and related services such as lab work, monitoring, and clinical follow-up. In many of these programs, the bill also bars cost-sharing, deductibles, coinsurance, and prior authorization requirements for covered HIV prevention services, subject to limited therapeutic-equivalence exceptions for some private plans.
Beyond insurance coverage, the bill would prohibit life, disability, and long-term care insurers from denying coverage, raising premiums, or otherwise discriminating against individuals because they take medication to prevent HIV acquisition. It also directs the Department of Health and Human Services to create public education campaigns for both the public and health care providers, with an emphasis on culturally competent outreach in communities disproportionately affected by HIV, and to establish grant funding for states, tribes, territories, and eligible nonprofit entities to support PrEP and PEP access programs. The bill includes confidentiality protections so individuals can use these benefits under family plans without other enrollees being informed, and it creates a private right of action and federal enforcement provisions to address violations.
The bill would amend multiple federal statutes, including the Public Health Service Act, ERISA, the Internal Revenue Code, the Social Security Act, title 38 governing veterans’ benefits, title 10 governing military health care, and the Indian Health Care Improvement Act. Its practical effect would be to make HIV prevention services a required, broadly covered benefit in major public and private insurance systems and to reduce administrative and financial barriers that can limit uptake of PrEP and PEP. It also sets effective dates mainly beginning in 2027 for the coverage changes and authorizes appropriations for the education and grant programs.
Overall sentiment in the available record appears supportive and preventive in nature, with the bill framed as a public health access measure rather than a controversial benefit cut or tax change. The sponsor list is broad and bipartisan-leaning in the sense of multiple senators joining as cosponsors, and there is no recorded committee debate or vote history in the provided materials. The bill’s structure and findings suggest a strong emphasis on reducing HIV transmission, improving equity, and normalizing access to prevention care.
The main points of potential contention are likely to be cost, federal mandates on private and public insurers, and the scope of required coverage without cost-sharing or prior authorization. Insurers and employers may object to the administrative burden and the requirement to cover related services broadly, while states may be concerned about Medicaid and CHIP implementation timelines and any need for state legislation. Another possible issue is the bill’s explicit protection against insurance discrimination based on PrEP use, which could raise actuarial and regulatory questions for life, disability, and long-term care insurers.
The bill would substantially expand and standardize HIV prevention coverage across federal and private insurance systems by amending the Public Health Service Act, ERISA, the Internal Revenue Code, the Social Security Act, title 38, title 10, and the Indian Health Care Improvement Act. It would require coverage of FDA-approved HIV prevention drugs and associated services, generally without cost-sharing, deductibles, coinsurance, or prior authorization, and would add enforcement, reporting, and private litigation mechanisms to ensure compliance. It also would prohibit adverse underwriting treatment in life, disability, and long-term care insurance based on PrEP use and would create new federal grant and education programs to support access and awareness.
The available context suggests generally favorable sentiment toward the bill’s public health goals. The measure is presented as an access-and-prevention bill aimed at reducing HIV transmission, expanding coverage, and addressing disparities in PrEP and PEP use, and there is no recorded opposition, committee testimony, or vote history in the provided materials. The broad list of cosponsors also suggests interest in the proposal across a range of senators.
Likely areas of contention include the cost of mandating coverage without cost-sharing, the prohibition on prior authorization, and the bill’s reach into multiple insurance markets and public programs. Private insurers, employers, and some state administrators may object to the federal requirements, compliance reporting, and potential litigation exposure. The ban on insurance discrimination based on PrEP use could also be debated by life, disability, and long-term care insurers because it limits underwriting practices based on medication use.